Prediction of Homologous Recombination Deficiency from Oncomine Comprehensive Assay Plus Correlating with SOPHiA DDM HRD Solution

- 3
- 4 Jun Kang¹, Kiyong Na², Haeyoun Kang³, Uiju Cho⁴, Sun Young Kwon⁵, Sohyun Hwang⁶,
- 5 Ahwon Lee^{1,7}, The Molecular Pathology Study Group of Korean Society of Pathologists

- ⁷ ¹Department of Hospital Pathology, Seoul St. Mary's Hospital, College of Medicine, The
- 8 Catholic University of Korea, Seoul, Korea
- 9 ²Department of Pathology, Kyung Hee University College of Medicine, Kyung Hee
- 10 University Hospital, Seoul, Republic of Korea
- ³Department of Pathology, CHA Bundang Medical Center, CHA University, Seongnam,
 Korea
- ⁴Department of Pathology, St. Vincent's Hospital, College of Medicine, The Catholic
- 14 University of Korea, Seoul, Korea
- ⁵Department of pathology, Dongsan Hospital, School of Medicine, Keimyung University
- ⁶CHA Future Medicine Research Institute, CHA Bundang Medical Center, Seongnam, Korea
- ¹⁷ ⁷Cancer Research Institute, The Catholic University of Korea, Seoul, Korea
- 18
- 19 Short title: Prediction of HRD
- 20
- 21 Corresponding author

- 22 Ahwon Lee
- 23 Professor
- 24 Department of Hospital Pathology
- 25 Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea
- 26 222, Banpo-daero, Seocho-gu, Seoul, 06591, Republic of Korea
- 27 Phone: +82-2-2258-1626
- 28 Fax: +82-2-2258-1627
- 29 E-mail: <u>klee@catholic.ac.kr</u>

31 ABSTRACT

32 **Objective** Poly(ADP-ribose) polymerase (PARP) inhibitors are used for targeted therapy for 33 ovarian cancer with homologous recombination deficiency (HRD). In this study, we aimed to 34 develop a homologous recombination deficiency prediction model to predict the genomic 35 integrity (GI) index of the SOPHiA DDM HRD Solution from the Oncomine Comprehensive 36 Assay (OCA) Plus. We also tried to a find cut-off value of the genomic instability metric 37 (GIM) of the OCA Plus that correlates with the GI index of the SOPHIA DDM HRD Solution. 38 **Methods** We included 87 cases with high-grade ovarian serous carcinoma from five tertiary 39 referral hospitals in Republic of Korea. We developed an HRD prediction model to predict 40 the GI index of the SOPHiA DDM HRD Solution. As predictor variables in the model, we 41 used the HRD score, which included percent loss of heterozygosity (%LOH), percent 42 telomeric allelic imbalance (%TAI), percent large-scale state transitions (%LST), and the 43 genomic instability metric (GIM), provided by the OCA Plus. To build the model, we 44 employed a penalized logistic regression technique.

Results The final model equation is $-21.77 + 0.200 \times \text{GIM} + 0.102 \times \% \text{LOH} + 0.037 \times \% \text{TAI}$ + 0.261 × %LST. To improve the performance of the prediction model, we added a borderline result category to the GI results. Cases with predicted values between -3 and 3 were classified as borderline. The accuracy of our HRD status prediction model was 0.947 for the training set and 0.958 for the test set. The accuracy of HRD status using GIM with a cut-off value of 16 was 0.911.

51 Conclusions The Oncomine Comprehensive Assay Plus provides a reliable biomarker for
52 homologous recombination deficiency.

54 What is already known on this topic

- 55 The Oncomine Comprehensive Assay Plus is a targeted next-generation sequencing assay
- 56 designed to detect genetic alterations in solid tumors. It has not been validated as a biomarker
- 57 for PARP inhibitor response through clinical trials or a concordance test with a Food and
- 58 Drug Administration–approved homologous recombination deficiency test.

59 What this study adds

- 60 This study introduces a predictive model for homologous recombination deficiency using
- 61 data from the Oncomine Comprehensive Assay Plus, which correlates with the SOPHiA
- 62 DDM HRD Solution. The study provides evidence that the Oncomine Comprehensive Assay
- 63 Plus is a reliable biomarker for homologous recombination deficiency.

64 How this study might affect research, practice or policy

- 65 The strong agreement between the Oncomine Comprehensive Assay Plus and the SOPHiA
- 66 DDM HRD Solution supports its potential as a biomarker for predicting PARP inhibitor
- 67 response. This finding could have implications for PARP inhibitor-related research, clinical
- 68 practice, and regarding their use in clinical trials.
- 69
- 70
- 71
- 72
- 73

74 INTRODUCTION

75 Homologous recombination repair (HRR) is a DNA repair mechanism that restores DNA 76 double-strand breaks (DSBs) in cells. This mechanism is essential for maintaining genomic 77 stability and preventing the accumulation of DNA damage that can lead to mutations and 78 other genetic alterations. When HRR is impaired, such as through mutations in genes 79 involved in this repair pathway, it can lead to a condition known as homologous 80 recombination deficiency (HRD). HRD has been found to be associated with an increased risk of developing certain types of cancer, including ovarian, breast, and prostate cancer¹². 81 82 The genes most commonly associated with HRD are *BRCA1* and *BRCA2*, which are tumor suppressor genes that play a critical role in HRR³. Mutations in these genes can impair the 83 84 HRR pathway, leading to an increased risk of developing cancer. Other genes involved in 85 HRR, such as PALB2 and RAD51, have also been linked to HRD and an increased cancer risk⁴⁵. 86

Poly(ADP-ribose) polymerase (PARP) inhibitors such as olaparib and talazoparib are a type of targeted therapy that work by inhibiting the function of poly(ADP-ribose) polymerase 1 (PARP1), an enzyme that is involved in the repair of single-strand DNA breaks (SSBs). PARP inhibitors have shown clinical efficacy in BRCA1/2 mutant ovarian cancer, breast cancer, and prostate cancer⁶⁻⁹. These drugs have demonstrated promising results in clinical trials and have been approved by regulatory agencies for the treatment of certain types of cancer.

94 HRD can lead to abnormal DSB repair and result in genomic scars, which are large95 scale genomic alterations that can be quantified by counting the number of occurrences.
96 There are several types of genomic scars associated with HRD, including large-scale loss of
97 heterozygosity (LOH)¹⁰, telomere allelic imbalance (TAI)¹¹, and large-scale state transitions

98 $(LST)^{12}$. The HRD score is a quantification of these genomic scars and is used to identify 99 patients who may benefit from treatment with PARP inhibitors¹³ ¹⁴. The HRD score is 100 calculated based on the occurrence of these genomic scars. These tests, such as the Myriad 101 myChoice CDx and FoundationOne CDx tests, have been approved by regulatory agencies as 102 companion diagnostics for PARP inhibitor treatment in patients with ovarian and prostate 103 cancer^{6 8 15 16}.

104 The SOPHiA DDM HRD Solution is a HRD test that identifies HRR mutations 105 through targeted sequencing and measures genomic instability (GI) through a combination of 106 low-pass whole-genome sequencing and a deep-learning algorithm¹⁷. The GI index is a 107 measure of genomic stability of the SOPHiA DDM HRD Solution. This index is based on the 108 analysis of the genome-wide patterns of copy number variations (CNVs) and is used to 109 determine the level of GI in a tumor sample. A high GI index indicates a high level of GI and 110 is associated with HRD tumors¹⁷.

111 The Oncomine Comprehensive Assay (OCA) Plus is a targeted next-generation 112 sequencing (NGS) assay designed to detect genetic alterations in solid tumors. The HRD 113 score provided by the OCA includes (1) percent LOH (%LOH), which estimates the fraction 114 of the genome with LOH identified using genomic segmentation; (2) percent TAI (%TAI), 115 which estimates the fraction of the genome with allelic imbalance or unequal contribution 116 from the two alleles in the telomeres identified using genomic segmentation; and (3) percent 117 LST (%LST), which estimates the fraction of the genome with unequal copy numbers in 118 adjacent segments identified using genomic segmentation. These values range from 0 to 100. 119 The genomic instability metric (GIM) is a proprietary measurement that quantifies genomic 120 scarring associated with HRD.

121 In this study, we aimed to develop an HRD prediction model to predict the GI index 122 of the SOPHiA DDM HRD Solution from the OCA Plus. We also tried to find a cut-off value 123 of the GIM of the OCA Plus that correlates with the GI index of the SOPHiA DDM HRD 124 Solution.

125

126 **METHODS**

127 Sample Collection

128 We included 87 cases of high-grade ovarian serous carcinoma from five tertiary referral 129 hospitals in Republic of Korea. All cases had been tested with OCA Plus NGS panel for 130 clinical purpose at the hospitals where patients were treated. We excluded the cases that failed 131 to analyze HRD scores provided by the OCA Plus. In all cases, we confirmed the clinical 132 information and tissue diagnosis and we selected paraffin blocks for the SOPHIA DDM HRD 133 Solution. We cut all formalin-fixed paraffin-embedded (FFPE) tissue samples to a thickness 134 of 5 µm. We sent 10 sections to the institution in the Republic of Korea that performs the 135 SOPHiA DDM HRD Solution.

136

137 Oncomine Comprehensive Assay Plus

We extracted genomic DNA by using the Maxwell RSC DNA FFPE Kit (Promega, Madison,
WI, USA) in accordance with the instructions provided by the manufacturer. We determined
the DNA concentration by using the Qubit ds DNA High-Sensitive Assay kit (Thermo Fisher
Scientific, Waltham, MA, USA) on the Qubit fluorometer (Thermo Fisher Scientific).

142 We performed all manual library preparation by using the OCA Plus system (Thermo

143 Fisher Scientific), following the manufacturer's instructions. We conducted the multiplex 144 polymerase chain reaction (PCR) amplification with an approximate DNA concentration of 145 20 ng. Prior to PCR amplification, we carried out the deamination reaction in the OCA Plus 146 by using Uracil-DNA Glycosylase, heat labile (Thermo Fisher Scientific). 147 For sequencing, we loaded the prepared libraries onto Ion 550 Chips (Thermo Fisher 148 Scientific) according to the manufacturer's instructions and processed them using the Ion 149 Chef System. We used the Ion S5 XL Sequencer (Thermo Fisher Scientific) for sequencing. 150 We aligned the data to the human genome assembly 19, which served as the standard 151 reference genome in the Ion Reporter Software (v. 5.18) (Thermo Fisher Scientific). Hospital 152 B utilized the customized variability control informatics baseline (VCIB) for copy number

analysis. The GIM was obtained from the Ion Reporter Software (v. 5.20).

154

155 Genomic Instability Score Prediction Modeling

We developed an HRD prediction model that aimed to predict the GI index of the SOPHiA DDM HRD Solution. The training set consisted of cases from hospital A, while the test set comprised cases from the other hospitals. The predictor variables used in the model were the HRD score, which included %LOH, %TAI, %LST, and the GIM, provided by the OCA Plus. To build the model, we employed a penalized logistic regression technique. We selected the model through repeated fivefold cross-validation on a grid of hyperparameters: λ (10⁻⁵, 10⁻⁴, 10⁻³, 10⁻², and 10⁻¹) and α (0.0, 0.25, 0.5, 0.75, and 1.0).

163

164 Assessing Model Performance

165	We estimated the performance of the prediction based on the area under the curve of the
166	receiver operating characteristic curve (AUROC) for the GI status and the HRD status. We
167	considered the GI status to be positive when the GI index exceeded 0. On the other hand, we
168	considered the HRD status to be positive if there was a BRCA1/2 pathogenic variant or if the
169	GI status was positive. We conducted the modeling and assessment of model performance
170	using the tidymodels and glmnet R packages. A flowchart of the study is presented in
171	Supplemental Figure 1.
170	In accordance with the journal's guidelines, we will provide our date for independent

In accordance with the journal's guidelines, we will provide our data for independent analysis by a selected team by the Editorial Team for the purposes of additional data analysis or for the reproducibility of this study in other centers if such is requested.

175

176 Research Ethics and Patient Consent

The study was approved by the Institutional Review Board of the CHA Bundang Medical
Center, CHA University (2023-01-010-001) and the Catholic University of Seoul Saint
Mary's Hospital (KC18TNSI0361), where this study was organized.

180

181 **RESULTS**

182 **Patients**

The average age of the patients was 59.3 years. The majority of patients had advanced disease based on the The International Federation of Gynecology and Obstetrics (FIGO) stage. Hospital A contributed the most cases (55, accounting for 63.2% of the total). There were no significant statistical differences in patient age and the FIGO stage between the train set and

187 the test set, as shown in Table 1.

188

189 SOPHiA DDM HRD Solution

- 190 The HRD status was positive in 56 cases (64.4%), negative in 23 cases (26.4%), and
- undetermined in 8 cases (9.2%). The GI status was positive in 50 cases (57.5%), negative in
- 192 27 cases (31.0%), and undetermined in 10 cases (11.5%). The BRCA status was positive in
- 193 28 cases (32.2%), negative in 45 cases (51.7%), and undetermined in 14 cases (16.1%).

194

195 Oncomine Comprehensive Assay Plus Sequencing

The mean of the average base coverage was 2469.64. The mean of the median absolute pairwise difference (MAPD) was 0.24. The MAPD is a metric that measures read coverage noise detected across all amplicons in a panel. A higher MAPD typically indicates lower coverage uniformity, which can result in missed or erroneous CNV calls. The quality control parameter metrics are summarized in Online Supplemental Table 1.

201

202 BRCA1/2 Pathogenic Variants

The concordance rate for BRCA1/2 pathogenic variants between the SOPHiA DDM HRD Solution and the OCA Plus was 95.9%. The discordant cases included two frameshift variants at homopolymer sequences. The OCA Plus pipeline filtered out these pathogenic variants due to an unusual prediction filter that measured the amount of strand bias according to the manufacturer's specifications. These two frameshift variants were restored by modifying the parameter of the unusual prediction filter. The other discordant variant was a long deletion.

- The long deletion could not be detected because it spanned across the ends of amplicons. Thepathogenic variants found in BRCA1/2 are listed in Online Supplemental Table 2.
- 211

212 Selecting Model and Performance Estimation

213 After excluding cases without a GI index from the SOPHiA DDM HRD Solution, the training 214 set and test set consisted of 51 and 26 cases, respectively. The model with a penalty of 0.1 215 and a mixture of 1 (Lasso regression) demonstrated the best performance in terms of the 216 AUROC in a repeated fivefold cross-validation (Supplemental Figure 2). We fit the final 217 model with the selected hyperparameters using the entire training set. The final model 218 equation is $-21.77 + 0.200 \times \text{GIM} + 0.102 \times \text{LOH}(\%) + 0.037 \times \text{TAI}(\%) + 0.261 \times \text{LST}(\%)$. 219 To improve the performance of the prediction model, we added a borderline result category to 220 the GI results. We classified cases with predicted values between -3 and 3 as borderline 221 (Figure 1). The accuracy of our HRD status prediction model was 0.947 for the training set 222 and 0.958 for the test set. Detailed performance metrics are summarized in Table 2.

223

224 Genomic Instability Metric

The AUROC for the GI status of SOPHiA DDM HRD Solution was 0.887 (Figure 2A). We set the positive cut-off value at 16 (Figure 2B). The accuracy of the HRD status using the GIM with a cut-off value of 16 was 0.911. Detailed performance metrics are summarized in Table 4.

229

230 DISCUSSION

231 Summary of Main Results

232 In this study, we developed a penalized linear regression model using the OCA Plus, which 233 showed a high concordance rate with the SOPHiA DDM HRD Solution. We also observed 234 that the GIM of the OCA Plus demonstrated high accuracy compared with the SOPHiA DDM 235 HRD Solution. Despite being independently developed by different manufacturers, the GIM 236 of the OCA Plus and the GI index of the SOPHiA DDM HRD Solution exhibited a high 237 concordance rate. These findings suggest that both tests capture the same tumor characteristic, 238 namely genomic alteration associated with HRD. When two different tests yield the same 239 results, it reinforces the certainty of the results. It also indicates that both tests are reliable and 240 reproducible.

241

242 **Results in the Context of Published Literature**

It is important to note that neither the OCA Plus nor the SOPHiA DDM HRD Solution has been validated as a biomarker for PARP inhibitor response through clinical trials. Both the OCA Plus and the SOPHiA DDM HRD Solution require clinical validation through a clinical trial or a concordance test with a Food and Drug Administration–approved HRD test.

The SOPHiA DDM HRD Solution exhibited a considerable rate of failure, resulting in an undetermined result. This failure rate is similar to that of the myChoice HRD Plus assay¹⁵. Additionally, the OCA Plus fails to analyze HRD scores, and our prediction model relies on the OCA Plus HRD scores. Our prediction model includes a borderline category, which does not definitively determine the GI status. However, the GIM also demonstrated high accuracy without the need for a borderline category.

253

254 Strengths and Weaknesses

255 In three cases (4%), the OCA Plus failed to detect BRCA1/2 pathogenic variants. Two of

256 these were c.2175del [chr13:32910667del] and c.3503dup [chr17:41244048dup] and were 257 filtered out due to the application of a filter related to strand bias originating from 258 homopolymer sequences. These false negatives were restored by modifying the filter 259 parameter. The remaining one is the c.2593_2621del [chr17:41244928_41244956del] 260 mutation, a 26 base pair deletion located within the overlapping regions of the OCA Plus 261 amplicons. This type of long deletion seems to interfere with the generation of libraries 262 containing both amplicons carrying this mutation, resulting in the absence of sequencing 263 reads. It has been observed that the coverage depth of these two amplicons is relatively low 264 compared with the adjacent amplicon positions. It is anticipated that detecting this mutation 265 with the OCA Plus would be challenging. Therefore, interpretation of BRCA1/2 status results 266 should consider the limitations of the test. These two cases had high GI and were classified as 267 HRD positive.

Because the NGS study was not conducted on all patients with high-grade ovarian serous carcinoma, the patients included in this study may exhibit bias. However, the rates of BRCA1/2 pathogenic variant presence and positive HRD status are similar to those reported in a clinical trial of ovarian high-grade serous carcinoma using the myChoice HRD Plus assay (Myriad Genetic Laboratories).

We developed the penalized linear regression model by using a small training set and validated it with a small test set. This approach may lead to a model that is either too simplistic and underfits the data or too complex and overfits the data.

276

277 Implications for Practice and Future Research

The OCA Plus offers several advantages compared with HRD-specific tests. It enablescomprehensive analysis of genetic alterations, including single nucleotide variants (SNVs),

insertions and deletions (indels), CNVs, structural variations, the tumor mutation burden,
mismatch repair deficiency, and microsatellite instability. This broad coverage enhances the
ability to identify potential targeted treatments. The high accuracy between the OCA Plus and
the SOPHiA DDM HRD Solution supports its potential as a biomarker for predicting the
PARP inhibitor response and its application in clinical trials for PARP inhibitors. Additionally,
our study provides a cut-off value for the GIM of the OCA Plus that correlates with the
SOPHiA DDM HRD Solution, with a high accuracy of 0.911.

287

288 CONCLUSIONS

This study presents a homologous recombination deficiency prediction model from the Oncomine Comprehensive Assay Plus that correlates with the SOPHiA DDM HRD Solution. this study provides evidences that The Oncomine Comprehensive Assay Plus provides reliable biomarkers for homologous recombination.

293

294 **REFERENCES**

- 1. Nguyen L, Martens J, Van Hoeck A, et al. Pan-cancer landscape of homologous
 recombination deficiency: Cancer Biology, 2020.
- 297 2. von Werdt A, Brandt L, Schärer OD, et al. PARP Inhibition in Prostate Cancer With
 298 Homologous Recombination Repair Alterations. *JCO Precision Oncology*299 2021(5):1639-49. doi: 10.1200/PO.21.00152
- 300 3. Scully R, Livingston DM. In search of the tumour-suppressor functions of BRCA1 and
 301 BRCA2. *Nature* 2000;408(6811):429-32. doi: 10.1038/35044000
- 302 4. Rahman N, Seal S, Thompson D, et al. PALB2, which encodes a BRCA2-interacting

303 protein, is a breast cancer susceptibility gene. *Nat Genet* 2007;39(2):165-67. doi:

- 304 10.1038/ng1959
- 305 5. Sharan SK, Morimatsu M, Albrecht U, et al. Embryonic lethality and radiation
 306 hypersensitivity mediated by Rad51 in mice lacking Brca2. *Nature*307 1997;386(6627):804-10. doi: 10.1038/386804a0
- 308 6. Hussain M, Mateo J, Fizazi K, et al. Survival with Olaparib in Metastatic Castration309 Resistant Prostate Cancer. *New England Journal of Medicine* 2020;383(24):2345-57.
- 310 doi: 10.1056/NEJMoa2022485
- 311 7. Litton JK, Rugo HS, Ettl J, et al. Talazoparib in Patients with Advanced Breast Cancer and
 312 a Germline BRCA Mutation. *New England Journal of Medicine* 2018;379(8):753-63.
- doi: 10.1056/NEJMoa1802905
- 8. Moore K, Colombo N, Scambia G, et al. Maintenance Olaparib in Patients with Newly
 Diagnosed Advanced Ovarian Cancer. *New England Journal of Medicine* 2018;379(26):2495-505. doi: 10.1056/NEJMoa1810858
- 317 9. Robson M, Im S-A, Senkus E, et al. Olaparib for Metastatic Breast Cancer in Patients with
- a Germline BRCA Mutation. *New England Journal of Medicine* 2017;377(6):523-33.
- doi: 10.1056/NEJMoa1706450
- 10. Abkevich V, Timms KM, Hennessy BT, et al. Patterns of genomic loss of heterozygosity
 predict homologous recombination repair defects in epithelial ovarian cancer. *British Journal of Cancer* 2012;107(10):1776-82. doi: 10.1038/bjc.2012.451
- 323 11. Birkbak NJ, Wang ZC, Kim J-Y, et al. Telomeric Allelic Imbalance Indicates Defective
- 324 DNA Repair and Sensitivity to DNA-Damaging Agents. Cancer Discov
- 325 2012;2(4):366-75. doi: 10.1158/2159-8290.CD-11-0206
- 326 12. Popova T, Manié E, Rieunier G, et al. Ploidy and Large-Scale Genomic Instability

327	Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 Inactivation.
328	Cancer Res 2012;72(21):5454-62. doi: 10.1158/0008-5472.CAN-12-1470
329	13. Telli ML, Timms KM, Reid J, et al. Homologous Recombination Deficiency (HRD)
330	Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in
331	Patients with Triple-Negative Breast Cancer. Clin Cancer Res 2016;22(15):3764-73.
332	doi: 10.1158/1078-0432.CCR-15-2477
333	14. Watkins JA, Irshad S, Grigoriadis A, et al. Genomic scars as biomarkers of homologous
334	recombination deficiency and drug response in breast and ovarian cancers. Breast
335	Cancer Research 2014;16(3):211. doi: 10.1186/bcr3670
336	15. Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus Bevacizumab as First-Line
337	Maintenance in Ovarian Cancer. New England Journal of Medicine
338	2019;381(25):2416-28. doi: 10.1056/NEJMoa1911361
339	16. de Bono J, Mateo J, Fizazi K, et al. Olaparib for Metastatic Castration-Resistant Prostate
340	Cancer. New England Journal of Medicine 2020;382(22):2091-102. doi:
341	10.1056/NEJMoa1911440

342 17. Andre G, Coletta T, Pozzorini C, et al. A deep learning approach for improved detection
343 of homologous recombination deficiency from shallow genomic profiles: bioRxiv,

344 2022.

345

347 Table 1. Cases summary

	Overall	Training set	Test set	p value
Number of patients	87	55	32	
Age (mean (SD))	59.3 (10.3)	59.2 (10.5) 59.4 (10.2		0.946
FIGO stage (%)				0.875
1	7 (8.1)	5 (9.3)	2 (6.2)	
2	6 (7.0)	3 (5.6)	3 (9.4)	
3	63 (73.3)	40 (74.1)	23 (71.9)	
4	10 (11.6)	6 (11.1)	4 (12.5)	
Institution (%)				
Hospital A	55 (63.2)	55 (100.0)	0 (0.0)	
Hospital B	15 (17.2)	0 (0.0)	15 (46.9)	
Hospital C	10 (11.5)	0 (0.0)	10 (31.2)	
Hospital D	4 (4.6)	0 (0.0)	4 (12.5)	
Hospital E	3 (3.4)	0 (0.0)	3 (9.4)	

³⁴⁸ SD: standard deviation, FIGO: The International Federation of Gynecology and Obstetrics

350 Table 2. Performance metrics

HRD test	Ν	Accuracy	Sensitivity	Specificity	Positive	Negative	F1 score
					Predictive	Predictive	
					Value	Value	
HRD result (Train)	38	0.947 95% CI (0.823 - 0.994)	0.964	0.900	0.964	0.900	0.964
HRD result (Test)	24	0.958 95% CI (0.789 - 0.999)	0.938	1.000	1.000	0.889	0.968
HRD result (GIM)	79	0.911 95% CI (0.826 - 0.964)	0.964	0.783	0.915	0.900	0.939
GI result (Train)	33	0.97 95% CI (0.842 - 0.999)	1.000	0.909	0.957	1.000	0.978
GI result (Test)	23	0.87 95% CI (0.664 - 0.972)	0.786	1.000	1.000	0.750	0.880
GI result (GIM)	77	0.883 95% CI (0.79 - 0.945)	0.960	0.741	0.873	0.909	0.914

351 HRD: homologous recombination deficiency, HRD result (Train/Test): prediction model performance for HRD result of SOPHiA DDM

352 HRD Solution, GI: Genomic Integrity, GI Result (Train/Test): prediction model performance for GI result of SOPHiA DDM HRD Solution

353 F1 score: harmonic mean of the precision and recall, GIM: Genomic Instability Metric, HRD result/GI result (GIM): prediction performance

354 of GIM for HRD result/GI result of SOPHiA DDM HRD Solution

355 Acknowledgement

356 The authors thank Taeeun Kim for providing data acquisition.

357

358 Declaration of Conflicting Interests

359 The Authors declares that there is no conflict of interest.

361 Figure legends

- 362 Figure 1. Performance of the homologous recombination deficiency (HRD) prediction model.
- 363 The training set (A) and the test set (B) are shown. The black vertical lines represent
- borderline cut-off values (-3 and 3).
- 365 Figure 1. Receiver operating characteristic curve (ROC) for the genomic instability (GI)
- 366 status of the SOPHiA DDM HRD Solution (A). The threshold (cut-off value) was set at 16.
- 367 The black vertical line indicates a genomic instability metric (GIM) of 16. The black
- 368 horizontal line indicates a GI index of 0.



